Cogent Biosciences, Inc.
COGT
Rank in Stocks
#3343
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Share Price
$30.11
Last synced: 2026-10-19
Market Cap
$5.22B
Change (1 day)
2.00%
Change (1 year)
85.64%
Country
US
Trade Cogent Biosciences, Inc. (COGT)
Category
Healthcare
Earnings for Cogent Biosciences, Inc. (COGT)
Earnings in Jun 2026 TTM: $-377.18M
According to Cogent Biosciences, Inc. latest financial reports the company's current earnings are $-377.18M. In 2023 the company made an earning of $-192.41M, a decrease compared to its 2022 earnings that were of $-140.24M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Cogent Biosciences, Inc. from 2015 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-377.18M | 47.42% |
| 2024 | $-255.86M | 32.98% |
| 2023 | $-192.41M | 37.20% |
| 2022 | $-140.24M | 94.04% |
| 2021 | $-72.27M | -3.39% |
| 2020 | $-74.81M | 135.00% |
| 2019 | $-31.83M | -7.82% |
| 2018 | $-34.53M | 35.46% |
| 2017 | $-25.49M | 40.65% |
| 2016 | $-18.12M | 174.94% |
| 2015 | $-6.59M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,498.51% |
US
|
|
| $-3.09B | 718.44% |
US
|
|
| $-4.02B | 964.80% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -617.17% |
NL
|
